Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Prostate Adenocarcinoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Intervention Model: Sequential AssignmentIntervention Model Description: 3+3 DesignMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
This study is designed to determine the safety and tolerability of Entinostat with Enzalutamide for treatment of patients with castration-resistant prostate cancer. There will be two dose levels of Entinostat in combination with same dose of Enzalutamide. Patients will be followed during treatment a...
This study is designed to determine the safety and tolerability of Entinostat with Enzalutamide for treatment of patients with castration-resistant prostate cancer. There will be two dose levels of Entinostat in combination with same dose of Enzalutamide. Patients will be followed during treatment and 1 month post discontinuation.
Tracking Information
- NCT #
- NCT03829930
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Jianquig Lin, MD George Washington Cancer Center
Get Well Soon